Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tyrosyl-tRNA synthetase 2 (YARS2) is a mitochondrial enzyme responsible for ligating tyrosine to its cognate tRNA (tRNA^Tyr), an essential step in mitochondrial protein synthesis and normal respiratory chain function[2]. As a class I aminoacyl-tRNA synthetase, YARS2 forms homodimers and contains conserved domains for substrate and tRNA recognition[1][2]. Mutations in YARS2 cause mitochondrial syndromes such as myopathy, lactic acidosis, and sideroblastic anemia. While its canonical role is in translation, recent studies of related cytoplasmic forms suggest possible noncanonical roles in cell signaling and actin organization[3]. No specific drugs currently target YARS2, and loss of its function is associated with profound mitochondrial dysfunction and disease.
Enzyme inhibitors or small molecules could disrupt the aminoacylation of mitochondrial tRNA^Tyr, impairing mitochondrial translation and protein synthesis - Potential allosteric or competitive inhibition at the catalytic site
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tyrosyl-tRNA synthetase 2 (YARS2).